KKR and Impilo complete acquisition of Immedica Pharma

(CercleFinance.com) - KKR and Impilo, a Nordic healthcare investment firm, have announced the completion of their joint acquisition of Immedica Pharma.


The Stockholm-based pharmaceutical company focuses on the commercialization of drugs for rare diseases and specialty care products.

KKR and Impilo will continue to work together with Immedica's experienced management team to support the company's growth, as it continues to strengthen its leading position in the European rare disease space', says the group.

Kugan Sathiyanandarajah, Partner and Head of KKR's Strategic Growth Healthcare business in Europe, said: 'We remain committed to supporting Immedica's future growth as a rare disease player with a highly promising product portfolio and attractive international expansion prospects'.

Copyright (c) 2024 CercleFinance.com. All rights reserved.